MESO vs HRMY
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MESO · Mesoblast$14.27 ▲ 1.21%
HRMY · Harmony Biosciences$33.11 ▲ 1.97%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MESO -6.2%
- HRMY +4.1%
Head to head
| Metric | MESO | HRMY |
|---|---|---|
| Price | $14.27 | $33.11 |
| Change today | ▲ 1.21% | ▲ 1.97% |
| Market cap | $1.86B | $1.94B |
| Return, 3 months | -14.4% | -15.1% |
| Return, year to date | -20.9% | -11.5% |
| Return, 1 year | -2.3% | +5.3% |
| P/E (TTM) | – | 11.0 |
| P/B | 3.3 | 1.8 |
| P/E percentile vs own 5y | 1st | 36th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -3.8% | +30.3% |
| Net profit growth (YoY) | -2.2% | +89.6% |
| Gross margin | 86.1% | 75.4% |
| Operating margin | -42.6% | 24.0% |
| Net margin | -47.8% | 18.9% |
| Return on equity | -9.9% | 20.5% |
| Analyst target vs. price | +159.3% | +47.1% |
| Analyst buy share | 100% | 71% |
| RSI (14) | 51 | 31 |
| 30-day volatility | 71.5% | 43.0% |
| Max drawdown, 1 year | -43.0% | -34.5% |
| Trend read | Leaning bullish | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- HRMY is the largest of the group by market value.
- HRMY has returned the most over the past year.
- HRMY is growing revenue fastest.
- HRMY keeps the most profit per dollar of sales.
- HRMY has been the calmest stock over the last 30 days.